Clinical trialPhase 2 / Phase 3Unknown
Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody
Exploratory Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Hydrochloride Combined With Pd-1 Antibody: An Open-Label, Single-center, Single-arm Study
- Outcome
- Outcome unknown
- Phase
- Phase 2 / Phase 3
- Status
- Unknown
- Study type
- Interventional
- Start
- 8 April 2019
- Listed end
- 8 July 2021
- Enrollment
- 100 participants
- Sites
- 1
- Primary outcomes
- Progression-free Survival (PFS)
- Sponsor type
- Other government
- Results posted
- No
- Last update
- 5 June 2019
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The main objective was to evaluate the safety and efficacy of anlotinib hydrochloride combined with pd-1 antibody second-line and above in the treatment of advanced solid tumors
Detailed description public domain (ClinicalTrials.gov)
To observe the beneficial population and adverse reactions of anlotinib hydrochloride combined with pd-1 in the treatment of patients with advanced solid tumor, and to explore the safe and effective drug treatment dose in the combined program, so that more patients with advanced tumor with poor prognosis can benefit from the combined program